Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $100,201.97PUBT·Jul 17 at 12:16 PMAQST+2.08%
BTIG’s Brisebois Reiterates Buy on Aquestive Therapeutics, Calling Sell-Off Overdone After SPRY Payer Update and Highlighting Limited Scope of FDA CRL for AnaphylmTip Ranks·Jun 25 at 11:55 AMAQST+2.08%
Aquestive Therapeutics director Julie Krop disposes of 25,000 common shares for $125,392.5PUBT·Jun 24 at 10:12 AMAQST+2.08%
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcriptbenzinga_article·May 14 at 08:09 AMAQST+2.08%BIB-1.08%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·May 13 at 04:06 PMPOCI+3.37%AQST+2.08%
Aquestive Secures New Oaktree Term Loan to Fund AnaphylmTip Ranks·May 13 at 04:01 PMAQST+2.08%PBE-1.80%
Aquestive Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.benzinga_article·May 13 at 03:40 PMAQST+2.08%XLV-1.84%
Aquestive Therapeutic | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.45 MEarnings Watch·May 13 at 03:10 PMAQST+2.08%
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree | AQST Stock NewsStockTitan·May 12 at 12:31 AMAQST+2.08%XBI+0.79%
18:30 ETAQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuitprnewswire·May 3 at 05:30 PMAQST+2.08%BIB-1.08%
